These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 1356224)

  • 1. U-M Cancer Center embarks on ovarian cancer drug study.
    Mich Med; 1992 Jun; 91(6):15. PubMed ID: 1356224
    [No Abstract]   [Full Text] [Related]  

  • 2. Taxol improves outlook for lung, breast, and ovarian cancer.
    Oncology (Williston Park); 1992 Aug; 6(8):16. PubMed ID: 1354469
    [No Abstract]   [Full Text] [Related]  

  • 3. Report from ASCO on taxol as second-line therapy for ovarian Ca.
    Oncology (Williston Park); 1990 Jul; 4(7):16. PubMed ID: 1975201
    [No Abstract]   [Full Text] [Related]  

  • 4. [Taxol and ovarian adenocarcinomas].
    Marty M; Extra JM; Culine S; Rousseau F
    Pathol Biol (Paris); 1992 Nov; 39(9):834-5. PubMed ID: 1347165
    [No Abstract]   [Full Text] [Related]  

  • 5. Taxol: an important new drug in the management of epithelial ovarian cancer.
    Markman M
    Yale J Biol Med; 1991; 64(6):583-90. PubMed ID: 1687343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian cancer--unrealistic expectations.
    Granai CO
    N Engl J Med; 1992 Jul; 327(3):197-200. PubMed ID: 1351658
    [No Abstract]   [Full Text] [Related]  

  • 7. Whom do yew trust?
    Langreth R
    Science; 1991 Jun; 252(5014):1780. PubMed ID: 1676541
    [No Abstract]   [Full Text] [Related]  

  • 8. [Paclitaxel (Taxol)--drug of choice in ovarian cancer].
    Fishman A
    Harefuah; 1996 Apr; 130(8):557-60. PubMed ID: 8765885
    [No Abstract]   [Full Text] [Related]  

  • 9. NICE approves Taxol for ovarian cancer.
    Kmietowicz Z
    BMJ; 2000 May; 320(7245):1293. PubMed ID: 10807610
    [No Abstract]   [Full Text] [Related]  

  • 10. Paclitaxel in advanced ovarian cancer: too much optimism?
    Bulusu VR; Allerton R
    Gynecol Oncol; 1997 Aug; 66(2):335-6. PubMed ID: 9264587
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients.
    Lehoczky O; Bagaméri A; Udvary J; Pulay T
    J Obstet Gynaecol; 2002 May; 22(3):312-3. PubMed ID: 12521509
    [No Abstract]   [Full Text] [Related]  

  • 12. [Chemotherapy of ovarian and breast cancer with Taxol].
    Dtsch Med Wochenschr; 1996 Dec; 121(50 Suppl):1-12. PubMed ID: 9022362
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 2000 Oct; 79(1):116-9. PubMed ID: 11006042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of paclitaxel in the first line treatment of cancer of the ovary?].
    Slimane K
    Bull Cancer; 2003 Mar; 90(3):202-3. PubMed ID: 12803089
    [No Abstract]   [Full Text] [Related]  

  • 15. Toward a chronotherapy of ovarian cancer with taxol. Part II: Test pilot study on circulating CA125.
    Halberg E; Long HJ; Cornélissen G; Blank MA; Elg S; Touitou Y; Bakken E; Delmore P; Haus E; Sackett-Lundeen L
    Chronobiologia; 1992; 19(1-2):17-42. PubMed ID: 1352750
    [No Abstract]   [Full Text] [Related]  

  • 16. Euro-Canadian study with taxol hits a record.
    Ann Oncol; 1992 Jun; 3(6):412. PubMed ID: 1353984
    [No Abstract]   [Full Text] [Related]  

  • 17. Taxol: a new agent active in melanoma and ovarian cancer.
    Einzig AI; Wiernik PH; Schwartz EL
    Cancer Treat Res; 1991; 58():89-100. PubMed ID: 1683787
    [No Abstract]   [Full Text] [Related]  

  • 18. Toward a chronotherapy of ovarian cancer with taxol. Part I: Basic background.
    Cornélissen G; Halberg E; Long HJ; Prem K; Bakken E; Touitou Y; Elg S; Haus E; Halberg F
    Chronobiologia; 1991; 18(4):153-66. PubMed ID: 1687729
    [No Abstract]   [Full Text] [Related]  

  • 19. [Second-line chemotherapy for ovarian cancer: the potential of Taxol].
    Maksimov SIa
    Vopr Onkol; 2002; 48(1):99-101. PubMed ID: 12101579
    [No Abstract]   [Full Text] [Related]  

  • 20. [A new, more expensive agent against ovarian cancer. Worth its price?].
    Högberg T; Karlsson G; Ridderheim M; Boman K; Frankendal B; Horvath G; Sorbe B; Strang P; Rosenberg P
    Lakartidningen; 1997 Jan; 94(1-2):21-4. PubMed ID: 9053597
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.